Nov 19, 2020
Integer porta, ipsum eget ultrices viverra, est purus semper diam, non lobortis tortor ipsum sit amet mauris. Aenean facilisis mollis erat, vitae efficitur lacus pellentesque rhoncus. Nam nulla massa, interdum ac erat quis, fermentum laoreet risus.
Nov 16, 2020
Moderna Inc. announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data.
Nov 13, 2020
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to patients once authorized or licensed by the Food and Drug Administration, the departments of Health and Human Services and Defense announced.
Nov 12, 2020
With the COVID-19 pandemic reaching the point in which vaccines against the coronavirus may soon be publicly available, the AHA is helping hospitals and health systems prepare for their arrival, while promoting public confidence in Food and Drug Administration-approved SARS-CoV-2 vaccines.
Nov 12, 2020
This is a set of resources to help hospitals and health systems reassure staff, patients and communities of COVID-19 vaccines’ safety and effectiveness. It includes messaging for many important audiences, whether organizational (stakeholders inside hospitals or health systems) or public-facing (…
Nov 11, 2020
The American Medical Association announced Current Procedural Terminology codes for reporting on medical claims two COVID-19 vaccines and their administration to patients by dose.
Nov 9, 2020
Pfizer Inc. announced that BNT162b2, its mRNA-based vaccine candidate, is more than 90% effective in preventing COVID-19, based on early data that has yet to be peer-reviewed.
Nov 3, 2020
German biotech firm CureVac N.V. announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.
Oct 29, 2020
The Centers for Medicare & Medicaid Services announced an interim final rule establishing additional Medicare hospital payment to support Medicare beneficiaries’ access to COVID-19 vaccines and new treatments when they become available.